Aadi Bioscience, Inc. (AADI)
$
2.05
-0.05 (-2.44%)
Key metrics
Financial statements
Free cash flow per share
-1.0229
Market cap
88.6 Million
Price to sales ratio
3.1887
Debt to equity
0
Current ratio
18.9518
Income quality
-1.4448
Average inventory
2.7 Million
ROE
0.2618
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of precision therapies targeting genetically defined cancers associated with mTOR pathway gene alterations. The company’s lead drug candidate, FYARRO, is a formulation of sirolimus bound to albumin that is currently under evaluation for its efficacy in cancers known to exhibit mTOR pathway activation. This includes tumor-agnostic indications aimed at specific genomic alterations that activate the mTOR pathway. The weighted average number of diluted shares outstanding is 27,029,942.00 reflecting potential dilution effects on existing shareholders. Furthermore, the operating expenses amount to $90,417,000.00 encompassing various operational costs incurred by the company during its research and development activities. As part of its financial obligations, the company incurred an income tax expense of $0.00 indicating its tax liabilities. The gross profit ratio is 0.88 which reflects the efficiency of the company's production and sales operations, while the income before tax ratio stands at -2.45 illustrating the firm’s pre-tax margin that indicates operational profitability prior to taxation. As of the current market analysis, the stock is affordable at $2.05 making it suitable for budget-conscious investors who are looking to participate in the potential upside of the company’s innovative therapies. The stock, however, has a low average trading volume of 200,709.00 indicating lower market activity, which may affect liquidity for some investors. With a market capitalization of $94,891,630.00 the company is classified as a small-cap player, highlighting its growth potential in a competitive industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, particularly in the realm of precision oncology. Moreover, it belongs to the Healthcare sector, which is driving innovation and growth as biotechnology and personalized medicine continue to advance, reflecting the ongoing evolution in cancer treatment methodologies and therapeutic options available to patients.
What is Aadi Bioscience, Inc. (AADI)'s stock forecast?
Analysts predict Aadi Bioscience, Inc. stock to fluctuate between $1.21 (low) and $3.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Aadi Bioscience, Inc.'s market capitalization?
As of 2025-03-18, Aadi Bioscience, Inc.'s market cap is $94,891,630, based on 46,288,600 outstanding shares.
How does Aadi Bioscience, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Aadi Bioscience, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Aadi Bioscience, Inc. (AADI) stock?
To buy Aadi Bioscience, Inc. (AADI) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AADI. Place an order (Market, Limit, etc.).
What is the best time to invest in Aadi Bioscience, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Aadi Bioscience, Inc. stock ever split?
Aadi Bioscience, Inc.'s last stock split was 1:15 on 2021-08-27.
How did Aadi Bioscience, Inc. perform in the last earnings report?
Revenue: $25,983,000 | EPS: -$2.36 | Growth: -3.28%.
Where can I find Aadi Bioscience, Inc.'s investor relations reports?
Visit https://aadibio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Aadi Bioscience, Inc.?
You can explore historical data from here
What is the all-time high and low for Aadi Bioscience, Inc. stock?
All-time high: $32.99 (2021-09-23) | All-time low: $1.21 (2024-08-08).
What are the key trends affecting Aadi Bioscience, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
2 months ago
New name reflects focus on accelerating portfolio of advanced ADC therapies with speed, agility and precision Upon closing of strategic transactions, cash expected to fund operations into 2028 enabling anticipated key clinical data readouts for its ADC assets Company shares to trade on Nasdaq under the symbol "WHWK" effective March 19, 2025 Company reports financial results for the fourth quarter and full-year 2024, and will host a conference call tomorrow, March 19 at 8:30 am ET MORRISTOWN, N.J. , March 18, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), formerly known as Aadi Bioscience, Inc., an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments, today announced it changed its name to Whitehawk Therapeutics, reflecting the Company's evolution and focus on accelerating its portfolio of antibody drug conjugates (ADCs) with speed, agility and precision.
prnewswire.com
3 months ago
MORRISTOWN, N.J. , March 14, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi") today announced that it will host a webcast to discuss fourth quarter and full-year 2024 financial results and provide recent corporate updates on Wednesday, March 19, 2025.
zacks.com
3 months ago
Aadi Bioscience (AADI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
prnewswire.com
3 months ago
MORRISTOWN, N.J. , March 4, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (Nasdaq: AADI) ("Aadi"), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced the closing of its previously announced private placement.
prnewswire.com
3 months ago
MORRISTOWN, N.J. , March 3, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver advances in cancer treatment, today announced that the Company's stockholders have approved all proposals voted on at the Company's Special Meeting of Stockholders ("Special Meeting") held on February 28, 2025.
zacks.com
3 months ago
Aadi Bioscience (AADI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com
3 months ago
MORRISTOWN, N.J. , Feb. 24, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) announced today its presentation at the TD Cowen 45th Annual Healthcare Conference, taking place March 3-5, 2025, in Boston, MA.
prnewswire.com
3 months ago
Seasoned Oncology Leader Brings Extensive ADC Expertise to Support Company's New Pipeline MORRISTOWN, N.J. , Feb. 18, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) today announced the appointment of David Dornan, PhD as the Company's Chief Scientific Officer (CSO).
prnewswire.com
4 months ago
Proxy Statement Includes Proposals on Previously Announced Sale of FYARRO and Associated Infrastructure to Kaken for $100M, and $100M PIPE Financing to Support In-Licensing of ADC Portfolio Aadi's Board Recommends Stockholders Vote "FOR" All Proposals to Support the Company's Business Transformation Company Expects to Close Transactions in the First Quarter of 2025, Subject to Stockholder Approval and Other Closing Conditions MORRISTOWN, N.J. , Feb. 5, 2025 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI) ("Aadi" or the "Company") announced it filed its definitive proxy statement with the U.S. Securities and Exchange Commission (the "SEC") on January 31, 2025, and today mailed its definitive proxy statement and a letter to stockholders, in connection with the Company's upcoming Special Meeting of Stockholders (the "Special Meeting") which is scheduled to be held on February 28, 2025.
benzinga.com
5 months ago
On Thursday, Aadi Bioscience, Inc. AADI entered into an exclusive license agreement for the development and global commercialization of a three-asset portfolio of preclinical antibody-drug conjugates (ADCs), in collaboration with WuXi Biologics and Hangzhou DAC Biotechnology Co., Ltd.
See all news
